stockrow
Saturday 7 November 2026
Export DRTS’s income statement to Excel — free account
Alpha Tau Medical Ltd.
DRTS Healthcare Biotechnology
- EPS
- −100.0%
- Free cash flow
- −30.4%
- Total debt
- +12.8%
Quarter to June 2026, against a year earlier
13.73
0.43
+3.23%
Follow DRTS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 13 | 74 | +783.9% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (8) | (9) | (27) | (34) | (29) | (32) | (43) | (44) | +31.2% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (8) | (9) | (27) | (34) | (29) | (32) | (43) | (88) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.25) | (0.22) | (0.67) | (0.53) | (0.42) | (0.45) | (0.53) | (0.56) | +13.3% | ||||||
| Cash flow | — | — | — | (0.20) | (0.18) | (0.29) | (0.38) | (0.26) | (0.28) | (0.33) | 0.00 | +8.4% | ||||||
| Capex | — | — | — | (0.04) | (0.09) | (0.07) | (0.01) | (0.09) | (0.03) | (0.08) | 0.00 | +12.0% | ||||||
| Free cash flow | — | — | — | (0.24) | (0.27) | (0.36) | (0.39) | (0.35) | (0.31) | (0.41) | 0.00 | +9.0% | ||||||
| Book value | — | — | — | 0.00 | (0.21) | (0.86) | 1.66 | 1.22 | 0.90 | 0.96 | 0.00 | n/m | ||||||
| Shares, m | — | — | — | 34 | 40 | 41 | 64 | 69 | 70 | 81 | 75 | +15.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (7) | (7) | (12) | (24) | (18) | (20) | (27) | (35) | +25.3% | |||||
| Capex | — | — | — | (1) | (4) | (3) | (1) | (6) | (2) | (6) | (4) | +29.4% | ||||||
| Free cash flow | — | — | — | (8) | (11) | (15) | (25) | (24) | (22) | (33) | (39) | +26.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 45 | 28 | 102 | 79 | 56 | 68 | 97 | +8.4% | |||||
| Net debt | — | — | — | — | (47) | (32) | (105) | (76) | (54) | (67) | (94) | +7.5% | ||||||
| Shareholders’ equity | — | — | — | — | (8) | (35) | 106 | 84 | 63 | 77 | 44 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (16.76) | (57.29) | (41.59) | (25.63) | (32.80) | (44.44) | 0.00 | (44.4) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | (7,250.90) | (268.77) | (261.11) | (255.98) | 0.00 | (256.0) pt | ||||||
| ROE | — | — | — | 0.00 | 105.37 | 126.24 | (95.27) | (30.67) | (43.16) | (61.00) | 0.00 | (61.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 83 | 94 | 121 | 112 | 121 | — | +127.2% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Alpha Tau Medical Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| URGN Urogen Pharma | $1.3B | — (loss-making) | — (loss-making) | +223.85% (above 0%: growing) | n/m | +63.95% (above 0%: growing) | 91.57% | 9.36% | Compare |
| OMER Omeros Corporation | $1.2B | 9.8× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.2B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +35.46% | — | −65.73% | 94.39% | 0.00% |